Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patritumab deruxtecan versus platinum-based chemotherapy after EGFR TKI failure in EGFR-mutated advanced NSCLC
NL-OMON60587Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of patritumab deruxtecan in non-small cell lung cancer (NSCLC), EGFR-mutated non-small cell lung cancer, sponsored by Daiichi Sankyo Co., Ltd.. Started Mar 2023; status: completed.
02
Drugs
patritumab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)EGFR-mutated non-small cell lung cancer
Beyond the preview
Go deeper on NL-OMON60587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60587.